Carolyn Considine
Family · West Hartford, CTNPI 1619400504
Payments from drug & device makers
Across 401 payments — averaging $18.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Abbott$704
- Dexcom, Inc.$655
- Amgen$556
- Xeris Pharmaceuticals, Inc.$511
- Lilly USA, LLC$495
- plus $2K from 34 others
What the payments were for
- Food & beverage$7,459100%
- Education$240%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 166 | $2,480 |
| Abbott | 40 | $704 |
| Dexcom, Inc. | 32 | $655 |
| Amgen(2 entities) | 20 | $556 |
| Xeris Pharmaceuticals, Inc. | 23 | $511 |
| Lilly USA, LLC | 27 | $495 |
| AbbVie | 12 | $221 |
| Boehringer Ingelheim | 8 | $167 |
| Sanofi-aventis U.S. LLC | 6 | $154 |
| Bayer | 6 | $149 |
| Embecta Corp. | 4 | $132 |
| Antares Pharma, Inc. | 6 | $131 |
| Corcept Therapeutics | 5 | $101 |
| Cequr Corporation | 3 | $91 |
| AstraZeneca | 4 | $83 |
| Amneal Pharmaceuticals LLC | 4 | $79 |
| Tandem Diabetes Care, Inc. | 3 | $76 |
| Madrigal Pharmaceuticals | 3 | $55 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $48 |
| Kyowa Kirin, Inc. | 2 | $46 |
| IBSA Pharma Inc. | 2 | $46 |
| Insulet Corporation | 2 | $45 |
| BETA Bionics, Inc. | 1 | $43 |
| Mannkind Corporation | 2 | $42 |
| Recordati_rare_diseases_inc. | 2 | $39 |
| Amarin Pharma, Inc. | 2 | $39 |
| Medtronic | 1 | $37 |
| Halozyme Inc | 1 | $27 |
| Intra-sana Laboratories | 1 | $24 |
| Esperion Therapeutics, Inc. | 1 | $24 |
| Exact Sciences | 1 | $24 |
| Novartis | 1 | $21 |
| Sequel Med Tech, LLC | 1 | $20 |
| GSK | 1 | $20 |
| Ascendis Pharma Endocrinology Inc | 1 | $19 |
| Azurity Pharmaceuticals, Inc. | 1 | $18 |
| Acerus Pharmaceuticals Corporation | 1 | $18 |
| EUSA Pharma (US) LLC | 1 | $17 |
| Ascensia Diabetes Care US Inc. | 1 | $16 |
| Currax Pharmaceuticals LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$362
- Ozempic$248
- TEPEZZA$178
- DEXCOM G6 TRANSMITTER$134
- GVOKE HYPOPEN$125
How this compares
$7,483 in reported general payments places this provider in the 95th percentile of 1,596 family providers in Connecticut.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 121 | $226,780 |
| Tresiba Flextouch U-200Insulin Degludec | 81 | $132,728 |
| MounjaroTirzepatide | 100 | $122,279 |
| RybelsusSemaglutide | 31 | $46,050 |
| JardianceEmpagliflozin | 27 | $45,280 |
| FarxigaDapagliflozin Propanediol | 23 | $29,872 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 17 | $26,867 |
| TrulicityDulaglutide | 16 | $21,162 |
| Tresiba Flextouch U-100Insulin Degludec | 31 | $19,343 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $15,996 |
| SynthroidLevothyroxine Sodium | 113 | $14,812 |
| Humalog Kwikpen U-100Insulin Lispro | 16 | $9,025 |
| Glucagon Emergency KitGlucagon | 12 | $6,047 |
| Novolog FlexpenInsulin Aspart | 18 | $4,951 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 32 | $4,695 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $2,480 | $272,830152 claims |
| Lilly USA, LLCMounjaro, Trulicity | $495 | $143,441116 claims |
| Boehringer IngelheimJardiance | $167 | $45,28027 claims |
| AstraZenecaFarxiga | $83 | $29,87223 claims |
| AbbVieSynthroid | $221 | $14,812113 claims |
| Amneal Pharmaceuticals LLCUnithroid, Levothyroxine Sodium | $79 | $2,797129 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,596 family providers in Connecticut.
Other family in West Hartford
- Milos TomicWest Hartford$8K
- Elisha ChristiansonWaterbury$371K
- Kathryn TierneyNew Britain$140K
- Jennifer SilvaSouth Windsor$91K
- Carli WillardEnfield$74K
- Erin MartinMilford$70K
- Dayna GiordanoNew Haven$65K
- Diana BytyqiDerby$53K
- Farhiya AbdiSouth Windsor$30K
- Nicole SandilandsBridgeport$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.